Dorzagliatin monotherapy in Chinese patients with type 2 diabetes: A dose-ranging, randomized, double-blind, placebo-controlled, phase 2 study
Zhu D et al. Lancet Diabetes Endocrinol 2018; Advance online publication. doi: 10.1016/S2213-8587(18)30105-0
Please follow the link below to view this article in full on a third-party website. Note that a subscription or payment may be required.